AbbVie's migraine drug meets main goal in head-to-head study with topiramate
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial.
The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began facing competition from several less expensive biosimilar versions.
The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, to show a lower discontinuation rate due to undesired effect from the treatment than topiramate.
Qulipta was stopped in 12.1% of patients, compared to 29.6% for the generic at 24 weeks.
The European Medicines Agency's safety committee had in 2023 recommended pregnant women not use topiramate-containing medicines to prevent migraine or manage their body weight as their newborns could have a higher risk of neurodevelopmental disorders.
AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches. In comparison, 39.3% patients on topiramate saw a similar reduction.
Qulipta, first approved in the United States in 2021, brought in $658 million in international sales last year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Kennedy's new US vaccine panel to discuss measles shot for children
(Reuters) -A new panel of U.S. vaccine advisers appointed by Health Secretary Robert F. Kennedy Jr. will vote on flu shots that contain a mercury-based preservative called thimerosal and discuss recommendations for measles shot at an upcoming meeting. The advisers to the Centers for Disease Control and Prevention will also vote on who should receive the shots for respiratory syncytial virus and influenza at the meeting scheduled for June 25 and 26, according to a draft agenda posted on CDC's website. Experts will discuss proposed recommendations whether a shot to prevent measles, mumps, rubella, and varicella (MMRV) should be given to children under 5 years of age. The agenda did not specify who will be presenting on MMRV or thimerasol at the meeting. Thimerosal has been used for decades in the United States in vials for medicines and vaccines that containing more than one dose, according to CDC.
Yahoo
2 hours ago
- Yahoo
Brazil poised to declare itself bird flu 'free,' state official says
By Ana Mano, Roberto Samora and Debora Ely SAO PAULO (Reuters) -Brazil is ready to declare the country free of the bird flu virus on commercial flocks, Edivilson Brum, the head of Rio Grande do Sul state's agriculture department, said on Wednesday in a statement. The 28-day countdown for reclaiming the country's disease-free status began on May 22 following the complete disinfection of the farm where Brazil's only commercial flock outbreak was detected last month. Under existing trade protocols, China and other importers banned chicken imports from Brazil, the world's largest exporter, pending measures to control the disease on commercial facilities. "We have fulfilled all the steps provided for in the health protocols so that Brazil can once again declare itself an influenza-free country to the World Organization for Animal Health," Brum said, referring to the highly pathogenic avian influenza virus (HPAI). The Brazilian ministry of agriculture did not have an immediate comment. Brazil's first outbreak hit a chicken breeder farm in Brazil's southernmost state of Rio Grande do Sul last month, triggering trade bans that may now be reversed with the regaining of the disease-free status. Reclaiming Brazil's status as free HPAI is not automatic and must be confirmed by the World Organization for Animal Health (WOAH), according to guidelines from the body.
Yahoo
4 hours ago
- Yahoo
AbbVie's migraine drug meets main goal in head-to-head study with topiramate
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began facing competition from several less expensive biosimilar versions. The study's main goal was for the company's drug Qulipta, also known as Aquipta in Europe, to show a lower discontinuation rate due to undesired effect from the treatment than topiramate. Qulipta was stopped in 12.1% of patients, compared to 29.6% for the generic at 24 weeks. The European Medicines Agency's safety committee had in 2023 recommended pregnant women not use topiramate-containing medicines to prevent migraine or manage their body weight as their newborns could have a higher risk of neurodevelopmental disorders. AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average number of days per month when they experience migraine headaches. In comparison, 39.3% patients on topiramate saw a similar reduction. Qulipta, first approved in the United States in 2021, brought in $658 million in international sales last year.
